Sponsors (2)
The bill aims to accelerate development of therapies for rare diseases and improve transparency and coordination among stakeholders, at the cost of modest federal spending and risks to agency workload, proprietary confidentiality, and potential conflicts of interest.
Patients with rare diseases gain coordinated scientific guidance from Foundation convenings that can speed development and review of new therapies.
Researchers and sponsors receive clearer alignment on trial design, endpoints, biomarkers, and use of natural history data, reducing development uncertainty and costs.
Public release of meeting content (transcripts, recordings, analyses) increases transparency, accountability, and public trust in regulatory-advisory interactions.
FDA staff time and participation in Foundation meetings could increase agency workload and divert review resources, potentially slowing other regulatory activities.
Involvement of industry and patient representatives risks perceived or actual conflicts of interest that could influence regulatory advice if not strictly managed.
Public release of meeting materials, even with protections, could lead to inadvertent disclosure of proprietary information and cause sponsors to withhold sensitive details.
Based on analysis of 2 sections of legislative text.
Requires FDA to partner with a Foundation to convene at least four annual multistakeholder science-focused meetings to advance development of drugs for rare diseases.
Introduced March 3, 2025 by Amy Klobuchar · Last progress March 3, 2025
Creates a new FDA-directed process, run through an outside Foundation, to hold recurring science-focused multistakeholder meetings that target development challenges for drugs to treat rare diseases. The Foundation must convene at least four meetings per year, each focused on a different rare disease or group of rare diseases, and maintain a permanent steering committee to select topics, solicit input, manage conflicts of interest, and advise implementation. Meetings will bring together academic researchers, clinicians, drug sponsors, scientific groups, and patient organizations to identify scientific approaches and align on issues such as trial design, endpoints, biomarkers, natural history use, and manufacturing to help streamline development and regulatory review for rare-disease therapies. The law directs the Secretary of Health and Human Services (through FDA) to arrange with the Foundation to carry out this program; the text does not specify additional funding or make meeting recommendations legally binding on FDA.